Markman on Oncology

 
 

  • PARP Inhibitors Promising as Ovarian Cancer Maintenance Therapy   Two recent trials have demonstrated that using a PARP inhibitor as a maintenance strategy for ovarian cancer substantially prolongs the time to subsequent disease progression.
  • What to Watch in Gynecologic Cancer   Dr Maurie Markman discusses some of the presentations on gynecologic malignancies at this year's ASCO meeting that he thinks will be the most interesting and provocative.
  • Palliative Care Does Not Necessarily Mean End-of-Life Care   What is palliative care? Dr Maurie Markman talks about the importance of changing perceptions so that 'palliative care' is not immediately associated with end-of-life care.
  • ASCO Policy Statement Supporting HPV Vaccination   Dr Maurie Markman explains his support for ASCO's recently published article supporting HPV vaccinations.
  • Detecting Ovarian Cancer: Study Suggests a Role for CA 125   A multimodal approach to ovarian cancer screening that includes CA 125 testing may reduce death from the disease, a Lancet study suggests.
  • Challenging the Mantra of Randomized Controlled Trials   Dr Maurie Markman discusses a recent observational study exploring the effect of adjuvant chemotherapy on outcomes in early-stage small cell lung cancer.
  • Moonshot to Cure Cancer: Hype or Hope?   The Obama Administration's 'moonshot' to cure cancer has drawn both admiration and skepticism among physicians. Dr Maurie Markman talks about what this ambitious effort can, and cannot, achieve.
  • Using Bevacizumab in High-Risk Cervical Cancer   Dr Maurie Markman discusses a paper showing that bevacizumab significantly improves overall survival rates in high-risk cervical cancer patients.
  • Ovarian Cancer Is Not a Death Sentence   Dr Markman comments on a recent study demonstrating that nearly a third of ovarian cancer patients live for 10 years and predicts that treatment advances will improve 10-year survival even more.
  • The Underutilization of Intraperitoneal Chemotherapy   Dr Maurie Markman expresses concern over a recent report illustrating the underuse of intraperitoneal chemotherapy for ovarian cancer, despite evidence that this therapy improves survival rates.
  • Adding Bevacizumab for Advanced Endometrial Cancer Dr Maurie Markman discusses the most clinically relevant research abstract on the gynecologic cancers as presented at ASCO 2015.
  • Gynecologic Cancers: New Regimens, Predictive Biomarkers   Dr Maurie Markman highlights a number of provocative trials assessing new treatment approaches to gynecologic cancer that will be presented at the 2015 ASCO annual meeting.
  • Olaparib Trial Offers a Look at Precision Medicine's Future   A recent trial of olaparib in ovarian cancer may be a landmark in the development of precision medicine, argues Dr Maurie Markman.
  • Survival After Surviving -- Estimating Late Recurrence Risk   How does recurrence risk change for a patient who has already survived ovarian cancer for a few years? Maurie Markman comments on a recent Journal of Clinical Oncology paper addressing the question.
  • Cervical Cancer Screening Rates 'Distressingly' Low   Dr Maurie Markman discusses a recent CDC survey revealing that 1 in 10 US adult women were not screened for cervical cancer during a recent 5-year period.
  • The Year in Gynecologic Cancer: Bevacizumab and Beyond Dr Maurie Markman highlights the most important developments and practice-changing clinical trials of 2014.
  • Too Soon for Broad BRCA Screening   Dr Maurie Markman discusses the controversy surrounding routine BRCA screening for breast and ovarian cancer and suggests that it is too soon for widespread genetic screening.
  • Bevacizumab's Role in Late-Stage Cervical Cancer   Dr. Maurie Markman discusses the recent FDA approval of bevacizumab for recurrent or late-stage cervical cancer and weighs the benefits of the drug in this setting against its toxicity profile.
  • The Molecular Tumor Board   Dr. Maurie Markman discusses the potential of 'molecular tumor boards' to interpret the genomic and genetic test results of cancer patients who do not have clear treatment options.
  • Reducing Patients' Symptom Burden in Cancer   Dr. Maurie Markman discusses the clinical importance of reducing ovarian cancer patients' symptoms, even when they do not clearly respond to treatment using typical measures like RECIST.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.